Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - Novartis
07.06.2025 02:35
Ad hoc announcement pursuant to Art. 53 LR
<ul><li>At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto pl… [+10952 chars]